Vasa Therapeutics is advancing VS-041, a matrix metalloproteinase inhibitor targeting heart failure with preserved ejection fraction, based on preclinical data showing reduced cardiac fibrosis and improved diastolic function. The compound has progressed to Phase 1c human trials with a favorable safety profile, addressing a significant gap in HFpEF treatment where ejection fraction remains normal despite functional decline.
Key Points
- VS-041 reduces cardiac fibrosis and improves diastolic function in preclinical models
- Oral small-molecule shows favorable safety profile in Phase 1 human trials
- FDA Fast Track designation granted for heart failure with preserved ejection fraction
Longevity Analysis
HFpEF represents a growing clinical challenge in aging populations, characterized by stiffened myocardium that impairs the heart's ability to relax and fill despite normal pumping strength. Targeting fibroinflammatory remodeling at the molecular level—rather than simply managing symptoms—addresses a fundamental mechanism of cardiac aging. The progression from preclinical validation through Phase 1 human safety establishes a foundation for testing whether blocking matrix metalloproteinase activity can slow or reverse the structural changes that limit cardiovascular function in older adults, a distinct advantage over current approaches that lack disease-modifying potential.
Original published by Longevity.Technology.